Key result
A protocol based on identification and monitoring of risk factors permits doxorubicin chemotherapy with little cardiac morbidity and virtually no mortality from drug-induced congestive failure.
Why the study?
Does a protocol based on identification and monitoring of risk factors prevent cardiac morbidity and mortality in cancer patients receiving doxorubicin?
Does a protocol based on identification and monitoring of risk factors prevent cardiac morbidity and mortality in cancer patients receiving doxorubicin?
A protocol based on risk factor identification and monitoring can minimize doxorubicin-induced cardiac morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
May support risk-stratified doxorubicin monitoring; leaves open need for prospective validation before practice change.
Michael R. Bristow (1982) conducted a review in Doxorubicin-induced cardiotoxicity. Protocol based on identification and monitoring of risk factors was evaluated on Cardiac morbidity and mortality from drug-induced congestive failure. A protocol based on identification and monitoring of risk factors permits doxorubicin chemotherapy with little cardiac morbidity and virtually no mortality from drug-induced congestive failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: